Projects: LiSyM Pillar II: Chronic Liver Disease Progression (LiSyM-DP), LiSyM network, LiSyM Pillar III: Regeneration and Repair in Acute-on-Chronic Liver Failure (LiSyM-ACLF), LiSyM Scientific Leadership Team (LiSyM-LT), LiSyM-Krebs Partnering
Institutions: Leibniz-Institut für Arbeitsforschung (IfADo)https://orcid.org/0000-0003-0695-3403
Junior Group Leader
Institutions: Leibniz-Institut für Arbeitsforschung (IfADo)https://orcid.org/0000-0002-6569-7676
This generic project is intended to be a forum for all LiSyM partner and external stakeholders interested in participating in the BMBF initiative LiSyM-Krebs.
Organisms: Not specified
In chronic diseases, at some point the liver can suddenly stop functioning. This is called acute-on-chronic liver failure, or ACLF. This is the leading cause of death in liver patients and is often provoked by the use of transcription or freely available drugs or alcohol abuse. For this condition we need an effective treatment quickly.
LiSyM-Pillar III researches the factors that contribute significantly to ACLF. What exactly happens then? Are there any early signs that would enable ACLF to be
In one in five people with NAFLD, the functioning liver cells, the hepatocytes, are replaced by connective tissue. Eventually this fibrosis becomes irreversible. In this state the liver is like a ‘scar that never heals’. Through it, the liver loses many of its vital functions.
LiSyM-Pillar II wants to know more about which factors promote fibrosis and the conditions under which fibrosis becomes irreversible How can fibrosis be diagnosed as early as possible? Researchers in the pillar are also
Dr. Ahmed Ghallab (TU University, Dortmund) deals with chronic liver damage caused by toxins. In addition, he investigates processes associated with cholestasis - when bile accumulates in the bile ducts. Ghallab has been able to explain basic mechanisms of acute cholestasis, using a method for intravital two-photon microscopy, which he developed.
Public web page: http://www.lisym.org/our-work/junior-group/the-liver-protects-itself
Start date: 1st Jan 2016
Dr. Nachiket Vartak (TU University, Dortmund) investigates the role of a particular protein - the GTPase Rab18 - in initiating NAFLD. He tries to influence Rab18 pharmacologically so that NAFLD is not initiated. Vartak also analyzes how bile acids leave the liver. He hopes to find ways to improve the flow of bile in a liver with dysfunctional bile flow.
Public web page: http://www.lisym.org/our-work/junior-group/the-protein-rab18
Start date: 1st Jan 2016